BCL2L1-AS1

Across TCGA pan-cancer cohorts, BCL2L1-AS1 RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated BCL2L1-AS1 data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher BCL2L1-AS1 RNA is associated with better overall survival. In most high-consensus cancer types, elevated BCL2L1-AS1 expression acts as an unfavorable survival marker, although some lineages such as STAD and UCS show a favorable association.

STAD, KIRC, and UVM are the cancer types where BCL2L1-AS1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Tertile	All	0.622	0.437	.006	44	view →
KIRC	DFS	Tertile	II,III,IV	0.436	0.636	.009	42	view →
UVM	DFS	Median	III,IV	0.208	0.740	.006	38	view →
UCS	DFS	Median	IV	0.952	0.367	.001	36	view →
SKCM	OS	Quartile	All	0.414	0.235	<.001	34	view →
ACC	DFS	Tertile	III,IV	0.592	0.335	.006	29	view →
CHOL	DFS	Tertile	All	0.748	0.264	.008	26	view →
LUAD	OS	Median	All	0.856	0.767	.007	24	view →
BLCA	OS	Tertile	All	0.778	0.647	.005	16	view →
UCEC	OS	Tertile	III,IV	0.751	0.875	.012	16	view →
THCA	OS	Quartile	II,III,IV	0.778	0.987	.008	10	view →
ESCA	OS	Median	All	0.628	0.769	.014	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

BCL2L1-AS1–STAD (OS)

Open the STAD breakdown →